Search research articles
Contact Us
Filters
Showing results (1-10 of 230) with videos related to
Page
of 23
Sort By:
Current Opinion in Oncology
|
April 9, 2014
Implementing precision medicine initiatives in the clinic: a new paradigm in drug development
Antoine Hollebecque, Christophe Massard, Jean-Charles Soria
Current Opinion in Oncology
|
March 14, 2012
Vascular disrupting agents: a delicate balance between efficacy and side effects
Antoine Hollebecque, Christophe Massard, Jean-Charles Soria
PPAR Research
|
April 15, 2009
Peroxisome proliferator-activated receptors in HBV-related infection
Laurent Dubuquoy, Alexandre Louvet, Antoine Hollebecque, et al.
Investigational New Drugs
|
December 18, 2013
Dysphonia induced by anti-angiogenic compounds
Erika Saavedra, Antoine Hollebecque, Jean-Charles Soria, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2015
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons
Antoine Hollebecque, David Malka, Charles Ferté, et al.
Expert Opinion on Investigational Drugs
|
March 1, 2021
Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers
Alice Boilève, Loïc Verlingue, Antoine Hollebecque, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 20, 2017
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Loic Verlingue, Antoine Hollebecque, Valérie Boige, et al.
Cancers
|
April 3, 2021
Immunotherapy in Advanced Biliary Tract Cancers
Alice Boilève, Marc Hilmi, Cristina Smolenschi, et al.
Hepatic Oncology
|
September 8, 2018
Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?
Thierry de Baere, Lambros Tselikas, Frederic Deschamps, et al.
Bulletin Du Cancer
|
December 19, 2022
Marine Valéry, Baptiste Cervantes, Cristina Smolenschi, et al.
Page
of 23
Search research articles
Search
Showing results (1-10 of 230) with videos related to
Sort By:
Page
of 23
Current Opinion in Oncology
|
April 9, 2014
Implementing precision medicine initiatives in the clinic: a new paradigm in drug development
Antoine Hollebecque, Christophe Massard, Jean-Charles Soria
Current Opinion in Oncology
|
March 14, 2012
Vascular disrupting agents: a delicate balance between efficacy and side effects
Antoine Hollebecque, Christophe Massard, Jean-Charles Soria
PPAR Research
|
April 15, 2009
Peroxisome proliferator-activated receptors in HBV-related infection
Laurent Dubuquoy, Alexandre Louvet, Antoine Hollebecque, et al.
Investigational New Drugs
|
December 18, 2013
Dysphonia induced by anti-angiogenic compounds
Erika Saavedra, Antoine Hollebecque, Jean-Charles Soria, et al.
European Journal of Cancer (Oxford, England : 1990)
|
January 7, 2015
Systemic treatment of advanced hepatocellular carcinoma: from disillusions to new horizons
Antoine Hollebecque, David Malka, Charles Ferté, et al.
Expert Opinion on Investigational Drugs
|
March 1, 2021
Rare cancer, rare alteration: the case of NTRK fusions in biliary tract cancers
Alice Boilève, Loïc Verlingue, Antoine Hollebecque, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 20, 2017
Matching genomic molecular aberrations with molecular targeted agents: Are biliary tract cancers an ideal playground?
Loic Verlingue, Antoine Hollebecque, Valérie Boige, et al.
Cancers
|
April 3, 2021
Immunotherapy in Advanced Biliary Tract Cancers
Alice Boilève, Marc Hilmi, Cristina Smolenschi, et al.
Hepatic Oncology
|
September 8, 2018
Advances in transarterial therapies for hepatocellular carcinoma: is novel technology leading to better outcomes?
Thierry de Baere, Lambros Tselikas, Frederic Deschamps, et al.
Bulletin Du Cancer
|
December 19, 2022
Marine Valéry, Baptiste Cervantes, Cristina Smolenschi, et al.
Page
of 23